Altimmune is a biotechnological company that develops vaccines and biological products to satisfy medical needs that have not been met. This company uses a patented technology for a non-invasive intranasal delivery that it has demonstrated through animal testing and preliminary clinical studies.
Truffle Capital first invested in Immune Targeting Systems (ITS), which was bought in February 2015 by Altimmune. ITS developed synthetic vaccines against mutant viruses. Its T-cell vaccine platform allowed it to target the retained parts of viruses (“antigens”) to bring about a T-cell immune response against the cells infected by these viruses.
Dr Philippe Pouletty is a Board member.